Trials / Conditions / Recurrent Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia

17 registered clinical trials studyying Recurrent Chronic Myelomonocytic Leukemia — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Recruiting	Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810	Mayo Clinic	Phase 1
Recruiting	Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic S NCT05549661	Mayo Clinic	Phase 1
Active Not Recruiting	Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia NCT04734990	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acu NCT04752163	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatmen NCT04375631	Fred Hutchinson Cancer Center	Phase 1
Active Not Recruiting	Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or C NCT04550442	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patien NCT04239157	M.D. Anderson Cancer Center	Phase 2
Completed	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or NCT04487106	M.D. Anderson Cancer Center	Phase 2
Recruiting	Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferativ NCT04493138	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Withdrawn	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem C NCT03807063	Fred Hutchinson Cancer Center	Phase 1
Recruiting	Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute My NCT04140487	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomo NCT03896269	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies NCT02530034	M.D. Anderson Cancer Center	Phase 1
Recruiting	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921	Fred Hutchinson Cancer Center	Phase 1
Terminated	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193	M.D. Anderson Cancer Center	Phase 2
Completed	Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leuk NCT01892371	M.D. Anderson Cancer Center	Phase 1 / Phase 2